In fiscal 2015, top selling drug in ophthalmic space in Japan was Eylea (62.7%
increase vs. 2014) and it jumped from second place to surpass the
former leader Lucentis (19.1% decrease vs. 2014).

Still, Lucentis is increasing sales generator for Novartis Japan 3-rd year in a row.

Lucentis Sales in Japan (2015-2013)
2015
276 billion yen (3-rd place in Novartis Japan top 10)
(276 000 000 000 yen)

2014
309 billion yen (4-th place in Novartis Japan top 10)

2013
193 billion yen (6-th place in Novartis Japan top 10)
Figures based on Japanese national health insurance prices.

Sources: Novartis Pharma K.K. Japan and EMS Japan

Copyright: Researchintokyo.com All rights reserved.